-- Telix Pharmaceuticals（ASX：TLX）週三發布聲明稱，其針對複發性膠質母細胞瘤的關鍵性Ipax BrIGHT試驗中，首例患者已接受候選藥物TLX101-Tx（碘-131-碘法蘭）的給藥。 該公司表示，研究旨在評估TLX101-Tx聯合化療與單獨化療相比的安全性和有效性。研究將招募首次復發且經影像學確診的膠質母細胞瘤患者。 該研究已獲得澳洲、奧地利、比利時和荷蘭的監管部門批准，該公司正在尋求更多地區的批准。 Telix Pharmaceuticals的股價在周三的交易中下跌超過6%。
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF